Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1976 1
1977 1
1981 3
1982 2
1983 8
1984 3
1985 7
1986 9
1987 4
1988 7
1989 13
1990 5
1991 8
1992 18
1993 13
1994 9
1995 13
1996 12
1997 14
1998 22
1999 22
2000 17
2001 19
2002 10
2003 11
2004 7
2005 10
2006 10
2007 9
2008 10
2009 7
2010 7
2011 6
2012 4
2013 2
2014 1
2015 4
2016 3
2017 5
2018 1
2020 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Results by year

Filters applied: . Clear all
Page 1
COX-1 and COX-2 inhibitors.
Hawkey CJ. Hawkey CJ. Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):801-20. doi: 10.1053/bega.2001.0236. Best Pract Res Clin Gastroenterol. 2001. PMID: 11566042 Review.
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Among authors: hawkey cj. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Clinical Trial.
Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, Struthers AD, Begg AG, Wei L, Avery AJ, Taggar JS, Walker A, Duce SL, Barr RJ, Dumbleton JS, Rooke ED, Townend JN, Ritchie LD, MacDonald TM; ALL-HEART Study Group. Mackenzie IS, et al. Among authors: hawkey cj. Lancet. 2022 Oct 8;400(10359):1195-1205. doi: 10.1016/S0140-6736(22)01657-9. Lancet. 2022. PMID: 36216006 Free article. Clinical Trial.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group. Bombardier C, et al. Among authors: hawkey cj. N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528. doi: 10.1056/NEJM200011233432103. N Engl J Med. 2000. PMID: 11087881 Free article. Clinical Trial.
Cyclooxygenase-2 inhibitors.
Hawkey CJ, Fortun PJ. Hawkey CJ, et al. Curr Opin Gastroenterol. 2005 Nov;21(6):660-4. doi: 10.1097/01.mog.0000182860.11669.04. Curr Opin Gastroenterol. 2005. PMID: 16220041 Review.
COX-2 inhibitors.
Hawkey CJ. Hawkey CJ. Lancet. 1999 Jan 23;353(9149):307-14. doi: 10.1016/s0140-6736(98)12154-2. Lancet. 1999. PMID: 9929039
Safety of acid-suppressing drugs.
Smallwood RA, Berlin RG, Castagnoli N, Festen HP, Hawkey CJ, Lam SK, Langman MJ, Lundborg P, Parkinson A. Smallwood RA, et al. Among authors: hawkey cj. Dig Dis Sci. 1995 Feb;40(2 Suppl):63S-80S. doi: 10.1007/BF02214872. Dig Dis Sci. 1995. PMID: 7859585 Review.
NSAIDs, coxibs, and the intestine.
Hawkey CJ. Hawkey CJ. J Cardiovasc Pharmacol. 2006;47 Suppl 1:S72-5. doi: 10.1097/00005344-200605001-00013. J Cardiovasc Pharmacol. 2006. PMID: 16785834 Review.
335 results